STAT3 and leukemia: Although there are difficulties to specifically directly target C/EBPβ [16], Withaferin A might potentially suppress C/EBPβ [47, 48], JMJD3 targets and upregulates C/EBPβ expression in leukemia [42], and JAK-STAT3 signaling can activate C/EBPβ [49].